摘要
目的:对胶原诱导性关节炎(collagen-induced arthritis,CIA)在不同性别、不同品系(SD大鼠、Wistar大鼠、Lewis大鼠)大鼠的发病情况进行比较研究,以期寻找出一种适合制作CIA模型的大鼠品系。方法:选用6周龄SPF级SD大鼠、Wistar大鼠各80只,Lewis大鼠40只,雌雄各半。采用尾根部皮下注射Ⅱ型胶原与不完全弗氏佐剂混合物的方法诱导出关节炎模型。结果:(1)不同种属发病率不同;随着免疫时间的延长,发病率越高。两两比较显示,SD和Wistar大鼠与Lewis大鼠发病率有显著性差异,但SD与Wistar无显著性差异;(2)不同品系大鼠AI不同,有显著性差异;组间两两比较结果显示:Lewis比SD、Wistar大鼠AI低,有显著性差异,且SD比Wistar大鼠AI高,差异亦具有显著性。但性别对AI没有影响;(3)性别对病理积分影响无显著性,种属对病理积分影响有显著性差异。两两比较结果显示,Lewis比SD、Wistar大鼠关节病理积分低,有显著性差异,而SD与Wistar大鼠之间无显著性差异。结论:在制作痹证(RA)大鼠模型时建议首选SD大鼠,其次可以选择Wistar大鼠,雌雄均可。
Objectives： Take collagen-induced arthritis（CIA） as experimental subject,make comparative study on gender and species to quest for the moderat method of making the CIA rat model.Methods：Choose SPF level forty female Sprague-Dawley（SD） and Wistar rats,twenty female Lewis rats,forty male SD and Wistar rats,twenty male Lewis.Use cattle Ⅱ type collagen to make the CIA animal model and compare the incidence of disease on gender and species.Results：（1）From the results of statistical analysis,we found that the incidence of different species are significant different;From the pairwise comparison,the SD and Wistar rats have notable differences compare with Lewis rats in the incidence of morbidity,but the SD and Wistar have no significant difference;（2） RMANOVA results shown that the AI of different species are significant different.From the pairwise comparison the SD rats have significant difference with Wistar and Lewis rats in AI.Gender have no effect of AI.Immune 28d within the time when compared with other time,there are significant difference.（3）Significance test shown that gender have no significant difference from pathological points but different species of rats have.Pairwise comparison test shown that Lewis have significant difference from SD and Wistar,but SD have no significant difference from Wistar.Conclusions：For the induction of CIA,we recommend the SD rat for CIA animal model.
出处
《中国中医基础医学杂志》
CAS
CSCD
北大核心
2010年第9期761-764,共4页
JOURNAL OF BASIC CHINESE MEDICINE
基金
国家科技支撑计划重点项目(2006BAI08B01-01)
“重大新药创制”科技重大专项(2009ZX09502-019)
